Injectable Platelet Rich Fibrin Versus Platelet Rich Plasma Injection in Degenerative Temporomandibular Joint

NCT07078006 | Completed

• 1 other identifier: 55653465
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The study aimed to compare the efficacy of injectable platelet rich fibrin (I-PRF) versus platelet rich plasma (PRP) injection in degenerative temporomandibular joint (TMJ).

Conditions

Platelet Rich Fibrin; Platelet Rich Plasma Injection; Degenerative Temporomandibular Joint

Outcome Measures

Primary Outcomes (1)

• Pain improvement

  Each patient will be instructed about postoperative pain assessment with the Visual Analogue Scale (VAS). VAS (0 represents "no pain" while 10 represents "the worst pain imaginable"). VAS was recorded preoperatively, immediately after the procedures, 1 month, 3 months, and 6 months postoperatively.

  6 months post-procedure

Secondary Outcomes (1)

• Assessment of tissue repair

  6 months post-procedure

Study Arms (2)

Group I

EXPERIMENTAL

Patients underwent arthrocentesis followed by a platelet-rich fibrin (PRF) injection using a conventional temporomandibular joint (TMJ) injection technique, aided by facial anatomical landmarks.

Other: Platelet Rich Fibrin

Group II

ACTIVE COMPARATOR

Patients underwent arthrocentesis followed by a platelet-rich plasma (PRP) injection using a conventional temporomandibular joint (TMJ) injection technique, aided by facial anatomical landmarks.

Other: Platelet Rich Plasma

Interventions

Platelet Rich Fibrin OTHER

Patients underwent arthrocentesis followed by a platelet-rich fibrin (PRF) injection using a conventional temporomandibular joint (TMJ) injection technique, aided by facial anatomical landmarks.

Group I

Platelet Rich Plasma OTHER

Patients underwent arthrocentesis followed by a platelet-rich plasma (PRP) injection using a conventional temporomandibular joint (TMJ) injection technique, aided by facial anatomical landmarks.

Group II

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age \>18 years old.
• Both sexes.
• Patients with unilateral or bilateral temporomandibular joint (TMJ) osteoarthritis according to magnetic resonance imaging (MRI) evaluation.

You may not qualify if:

• Patients under any type of antiplatelet or anticoagulant medications.
• Cardiovascular, renal, or hepatic disease.
• Diabetes.
• Anemia.
• Vascular insufficiency.
• Peripheral neuropathy.
• Previous surgery for TMJ and rheumatoid arthritis.

Sponsors & Collaborators

• Nasser Institute For Research and Treatment: lead

Study Sites (1)

Nasser

Cairo, 112345, Egypt

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Oral and Maxillofacial Surgery Department, Faculty of Oral & Dental Medicine, AL Azhar University, Assuit, Egypt.

Study Record Dates

• First Submitted: December 31, 2024
• First Posted: July 22, 2025
• Study Start: February 22, 2023
• Primary Completion: December 22, 2023
• Study Completion: July 23, 2024
• Last Updated: July 22, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)